Back to search results

Study on Neutrophils and Pneumococcal Vaccine Response in Adults

This study is looking at how a type of white blood cell called neutrophils affects the body's response to the Prevnar-13 vaccine, which protects against pneumonia. Researchers want to understand why older adults might not respond as well to vaccines as younger adults. They will give the Prevnar-13 vaccine to healthy volunteers, both young (21-40 years old) and older (65+ years old), who haven't had a pneumococcal vaccine before. The main goal is to see how well the neutrophils kill bacteria after vaccination and how this relates to the antibodies your body makes. The study is currently unclear on its recruitment status and plans to enroll 60 participants.

Study design
This is an interventional study with a planned enrollment of 60 participants. It compares the vaccine response in young and older adults.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 1 month after vaccination.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06128915

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

Recruiting
PHASE4Ages 21+InterventionalBasic science
State University of New York at Buffalo
~60 participants
Updated 2026-04-03 on ClinicalTrials.gov
What's tested:vaccine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pneumococcal Opsonophagocytic Killing Activity (OPH) by neutrophils from young versus old donors at 1 week and 1 month after vaccination
Measured over 1 month

Conditions

Aging

Explore related trials

Aging

NCT06128915

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University at Buffalo

    Buffalo, New Yorkno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Elsa N Bou Ghanem, PhD · PRINCIPAL_INVESTIGATOR · University at Buffalo

Who to contact

Elsa Bou Ghanem, PhD
[email protected]
7168292422
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Both sexes
Have not been vaccinated with any licensed or experimental pneumococcal vaccine
Ages 21-40; and ≥65. Individuals \>60 years old will also be recruited in case we find no unvaccinated people ≥65 years old
Free of acute infections within the last 2 weeks
Did not take any anti-inflammatory medicine in the last week
Did not ingest alcohol in the last 24 hours
Ability and willingness to provide consent

Exclusion

Previous vaccination with any licensed or experimental pneumococcal vaccine
Known hypersensitivity to vaccination and vaccine components
Immune deficiency
Use of immune-modulating or suppressive drugs
Malignancies within the last 2 years
Known hematological, rheumatic and inflammatory diseases
Known chronic infections
Poorly controlled chronic cardiovascular and metabolic conditions
Pregnancy
Dementia

What this trial measures

  • Pneumococcal Opsonophagocytic Killing Activity (OPH) by neutrophils from young versus old donors at 1 week and 1 month after vaccination1 month

    OPH will be determined by measuring the percentage of S. pneumoniae bacteria killed in vitro by neutrophils from donors